{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:36:31Z","timestamp":1792470991222,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.esmoop.2021.100309","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T14:34:43Z","timestamp":1637937283000},"page":"100309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Pan-Asian adaptation of the EHNS\u2013ESMO\u2013ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-4247","authenticated-orcid":false,"given":"B.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Golusinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gregoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Rajappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Azrif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.I.","family":"Wan Zamaniah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kiyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100309_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2021.100309_bib2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.canep.2018.10.014","article-title":"Incidence and mortality trends in oral and oropharyngeal cancer in China, 2005-2013","volume":"57","author":"Zhang","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.esmoop.2021.100309_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ijc.29330","article-title":"Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009","volume":"137","author":"Hwang","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2021.100309_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.21053\/ceo.2015.01123","article-title":"Trends in head and neck cancer in South Korea Between 1999 and 2012","volume":"9","author":"Suh","year":"2016","journal-title":"Clin Exp Otorhinolaryngol"},{"key":"10.1016\/j.esmoop.2021.100309_bib6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/jjco\/hyv088","article-title":"Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project","volume":"45","author":"Hori","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.esmoop.2021.100309_bib9","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1016\/S1470-2045(17)30460-6","article-title":"Defining a global research and policy agenda for betel quid and areca nut","volume":"18","author":"Mehrtash","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7314\/APJCP.2014.15.2.537","article-title":"Head and neck cancer: global burden and regional trends in India","volume":"15","author":"Mishra","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.esmoop.2021.100309_bib11","first-page":"476","article-title":"Cancers of the lung, head and neck on the rise: perspectives on the genotoxicity of air pollution","volume":"33","author":"Wong","year":"2014","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.esmoop.2021.100309_bib12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrc.2018.11","article-title":"The molecular landscape of head and neck cancer","volume":"18","author":"Leemans","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2021.100309_bib13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.canep.2015.09.013","article-title":"HPV-associated head and neck cancers in the Asia Pacific: a critical literature review & meta-analysis","volume":"39","author":"Shaikh","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.esmoop.2021.100309_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13027-018-0193-6","article-title":"Clinico-pathological features of oropharyngeal squamous cell carcinomas in Malaysia with reference to HPV infection","volume":"13","author":"Yap","year":"2018","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.esmoop.2021.100309_bib15","first-page":"1325","article-title":"Detection of human papilloma virus and risk factors among patients with head and neck squamous cell carcinoma attending a tertiary referral centre in South India","volume":"19","author":"Bandhary","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.esmoop.2021.100309_bib16","doi-asserted-by":"crossref","first-page":"86730","DOI":"10.18632\/oncotarget.13502","article-title":"High-risk HPV genotypes and P16INK4a expression in a cohort of head and neck squamous cell carcinoma patients in Singapore","volume":"7","author":"Tan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2021.100309_bib17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/sajc.sajc_181_17","article-title":"Oncology Gold Standard\u00ae practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck","volume":"6","author":"Babu","year":"2017","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.esmoop.2021.100309_bib18","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.4103\/0019-509X.278977","article-title":"Indian clinical practice consensus guidelines for the management of very advanced disease of squamous cell carcinoma of head and neck","volume":"57","author":"Prabhash","year":"2020","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.esmoop.2021.100309_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.21147\/j.issn.1000-9604.2019.01.05","article-title":"diagnosis and treatment guidelines for head and neck cancer 2018 (English version)","volume":"31","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100309_bib20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.anl.2017.02.004","article-title":"Japanese clinical practice guideline for head and neck cancer","volume":"44","author":"Nibu","year":"2017","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.esmoop.2021.100309_bib23","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.esmoop.2021.100309_bib25","series-title":"UICC TNM Classification of Malignant tumours","first-page":"17","article-title":"Head and neck tumours","author":"O\u2019Sullivan","year":"2017"},{"key":"10.1016\/j.esmoop.2021.100309_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.radonc.2011.03.004","article-title":"Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck\u2013a systematic review and meta-analysis","volume":"100","author":"Overgaard","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/jnci\/djy133","article-title":"Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck","volume":"111","author":"Bauml","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2021.100309_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13014-019-1235-y","article-title":"3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis","volume":"14","author":"Helfenstein","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib29","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","article-title":"Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial","volume":"36","author":"Noronha","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib30","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s00405-013-2749-9","article-title":"Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: a retrospective analysis of a tertiary institute experience","volume":"271","author":"Osman","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100309_bib31","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) - a Trans-Tasman Radiation Oncology Group study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2021.100309_bib32","article-title":"Phase II\/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008)","volume":"38","author":"Kiyota","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib33","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2021.100309_bib34","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100309_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/tro.2020.03.02","article-title":"New first-line treatment for recurrent or metastatic squamous cell carcinoma of head and neck: does one size fit all?","volume":"4","author":"Kiyota","year":"2020","journal-title":"Therap Radiol Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2021.06.039","article-title":"First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck: efficacy and safety results of the randomised, phase III CHANGE-2 trial","volume":"156","author":"Guo","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100309_bib37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s10147-020-01817-4","article-title":"Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2)","volume":"26","author":"Yokota","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fonc.2019.00006","article-title":"A\u00a0multicenter phase II trial of docetaxel, cisplatin, and cetuximab (TPEx) followed by cetuximab and concurrent radiotherapy for patients with local advanced squamous cell carcinoma of the head and neck (CSPOR HN01: ECRIPS Study)","volume":"9","author":"Zenda","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib39","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/annonc\/mdy040","article-title":"Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)","volume":"29","author":"Tahara","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2021.100309_bib40","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1200\/JCO.2019.37.15_suppl.6002","article-title":"TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC)","volume":"37","author":"Guigay","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib41","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100309_bib42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.oraloncology.2017.07.023","article-title":"A\u00a0randomized, open-label, phase III clinical trial of nivolumab vs. therapy of investigator\u2019s choice in recurrent squamous cell carcinoma of the head and neck: a subanalysis of Asian patients versus the global population in checkmate 141","volume":"73","author":"Kiyota","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib43","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1002\/hed.26331","article-title":"Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator\u2019s choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)","volume":"42","author":"Yen","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.esmoop.2021.100309_bib44","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib45","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/annonc\/mdq077","article-title":"Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and\/or metastatic squamous cell carcinoma of the head and neck","volume":"21","author":"Mesia","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib46","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100309_bib47","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2021.100309_bib48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jnci\/djaa063","article-title":"Quality of life with pembrolizumab for recurrent and\/or metastatic head and neck squamous cell carcinoma: KEYNOTE-040","volume":"113","author":"Harrington","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:36Z","timestamp":1761855936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921002714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2059702921002714"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100309","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-Asian adaptation of the EHNS\u2013ESMO\u2013ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100309"}}